Atopic dermatitis (AD) is a chronic inflammatory disease characterized by a complex interaction between genetic and environmental factors. Defects in cutaneous barrier (filaggrin gene) predispose to the immune-inflammatory condition. Emollients are a standard of care, steroid-sparing, and useful for both prevention and maintenance therapy in AD. AD-DER is an emollient formulated specifically for skin affected by AD, which contains several active agents (liquorice extract, niacinamide, xylitol, laureth-9-polydocanol) to target the underlying AD disease pathophysiology. The aim of the study was to evaluate the efficacy of AD-DER emollient cream in patients with AD by non-invasive techniques. 20 patients aged 18-65, affected by mild to moderate AD at remission, were enrolled in the study. While 10 patients received placebo, the others were treated with AD-DER for two months. Cutaneous hydration was measured by Corneometer (CM825), while Optical Coherence Tomography (OCT) was used to analyse vascularization, thickness and hydration. Corneometer 825 is based on the electric properties of stratum corneum in relation to the water content. OCT allows a cross-sectional imaging of the skin in situ and in real time, with 1-2 mm penetration depth. Corneometer revealed that AD-DER treatment increases hydration in the arms and legs of AD patients (p<0-05, p< 0.01, respectively at 1 and 2 months). OCT showed a significant reduction in hyper-reflectance of stratum corneum (typical of AD) and a modulation of the vascular plexus. All in all, these data support the role of AD-DER cream as an efficacious emollient for AD.